Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
The phase 2 trial provides evidence that dabrafenib combined with trametinib could serve as a more effective and safer first-line treatment option for pediatric low-grade gliomas with BRAF V600 mutations. Evaluate the data to consider how this may influence your treatment protocols.
Oncology, Medical September 25th 2023
Discover how base editing via CRISPR-guided cytidine deamination could revolutionize CAR T-cell therapy for T-cell cancers, offering a promising approach to treating relapsed or refractory cases in pediatric patients.
Hematology/Oncology September 11th 2023
OBR Oncology
Bridging the Gap: Twinning Programs Improve Pediatric Cancer Survival Rates Across Borders In a world where a few miles can determine the fate of a child with cancer, twinning programs are making a significant difference. These initiatives, which pair hospitals across borders, are helping to bridge the survival gap in pediatric acute leukemia between high-income and lower-income countries. Key Points: “There’s no pediatric centers in many of the mountain west states. If your kid gets cancer in Wyoming, you gotta go to Utah or Colorado or Mayo in Minnesota. But here, there’s really nice evidence that providing the right protocols, training, staff, and more, we could do this in more places and improve outcomes without developing a new drug.” Gwen Nichols, chief medical officer of the Leukemia and Lymphoma Society
Hematology/Oncology June 12th 2023
Twenty-seven (27) children with heavily pretreated neuroblastoma (12 with refractory disease, 14 with relapsed disease, and one with a complete response at the end of first-line therapy) were enrolled in this academic, phase 1-2 clinical trial to test autologous, third-generation GD2-CAR T cells expressing the inducible caspase 9 suicide gene (GD2-CART01). The use of GD2-CART01 in the treatment of high-risk neuroblastoma was feasible and safe. Treatment-related toxic effects emerged, and the suicide gene was activated to control side effects. GD2-CART01 may have long-term antitumor activity.
Oncology, Medical April 10th 2023
MDLinx
The first version of the test, launched in November 2022, assesses chromosomal copy number changes in blood, cerebrospinal fluid, and the aqueous humor of the eye to aid in the clinical diagnosis of patients with solid tumors, brain tumors, and retinoblastoma, respectively. The next version of the clinical assay, which will be available in about six months, will detect mutations and gene fusions.
Oncology, Medical March 6th 2023
Clinical Oncology News
The approval for the treatment of pediatric patients aged 2 years and older with previously untreated high-risk classic Hodgkin lymphoma (HL) was based on the AHOD1331 phase 3 study, which examined the effects of brentuximab vedotin (Adcetris, Seagen) in combination with the dose-intensive chemotherapy regimen AVE-PC (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide). Results showed that patients who received the AVE-PC combination had better event-free survival than those who received ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide). Patients experienced a 59% decrease in their risk of death, second cancer, or disease progression.
Hematology/Oncology November 28th 2022